

Georgia N Valsami

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3542478/publications.pdf>

Version: 2024-02-01

80
papers

1,746
citations

257450
24
h-index

315739
38
g-index

80
all docs

80
docs citations

80
times ranked

2204
citing authors

#	ARTICLE	IF	CITATIONS
1	Pro-inflammatory cytokines/chemokines, TNF α , IL6 and MCP1, as biomarkers for the nephro- and pneumoprotective effect of silibinin after hepatic ischemia/reperfusion: Confirmation by immunohistochemistry and qRT-PCR. Basic and Clinical Pharmacology and Toxicology, 2022, 130, 457-467.	2.5	5
2	Development of a Population Pharmacokinetic Model of Busulfan in Children and Evaluation of Different Sampling Schedules for Precision Dosing. Pharmaceutics, 2022, 14, 647.	4.5	4
3	Losartan Interactions with 2-Hydroxypropyl- β -CD. Molecules, 2022, 27, 2421.	3.8	4
4	A Comprehensive Review of the Cardiovascular Protective Properties of Silibinin/Silymarin: A New Kid on the Block. Pharmaceutics, 2022, 15, 538.	3.8	9
5	Exercise training inhibits atherosclerosis progression and reduces VE-cadherin levels within atherosclerotic plaques in hypercholesterolemic mice. Biochemical and Biophysical Research Communications, 2022, , .	2.1	0
6	Charting the structural and thermodynamic determinants in phenolic acid natural product α -cyclodextrin encapsulations. Journal of Biomolecular Structure and Dynamics, 2021, 39, 2642-2658.	3.5	9
7	Population pharmacokinetics of anidulafungin in ICU patients assessing inter- and intrasubject variability. British Journal of Clinical Pharmacology, 2021, 87, 1024-1032.	2.4	7
8	Omentin-1 and vaspin serum levels in patients with pre-clinical carotid atherosclerosis and the effect of statin therapy on them. Cytokine, 2021, 138, 155364.	3.2	7
9	The hepatoprotective effect of silibinin after hepatic ischemia/reperfusion in a rat model is confirmed by immunohistochemistry and qRT-PCR. Journal of Pharmacy and Pharmacology, 2021, 73, 1274-1284.	2.4	4
10	Flurbiprofen sodium microparticles and soft pellets for nose-to-brain delivery: Serum and brain levels in rats after nasal insufflation. International Journal of Pharmaceutics, 2021, 605, 120827.	5.2	9
11	Dose individualization of intravenous busulfan in pediatric patients undergoing bone marrow transplantation: impact and <i>in vitro</i> evaluation of infusion lag-time. Journal of Pharmacy and Pharmacology, 2021, 73, 1340-1350.	2.4	2
12	The cardiovascular protective properties of saffron and its potential pharmaceutical applications: A critical appraisal of the literature. Phytotherapy Research, 2021, 35, 6735-6753.	5.8	12
13	Nasal powders of quercetin- β -cyclodextrin derivatives complexes with mannitol/lecithin microparticles for Nose-to-Brain delivery: In vitro and ex vivo evaluation. International Journal of Pharmaceutics, 2021, 607, 121016.	5.2	27
14	Nonalcoholic fatty liver disease: The role of quercetin and its therapeutic implications. Saudi Journal of Gastroenterology, 2021, 27, 319-330.	1.1	10
15	Effect of silibinin on the expression of MMP2, MMP3, MMP9 and TIMP2 in kidney and lung after hepatic ischemia/reperfusion injury in an experimental rat model. Acta Cirurgica Brasileira, 2021, 36, e360904.	0.7	1
16	Application of Neutralization and Technique for the Preparation of the Beneficial Drug 2-Hydroxypropyl- β -Cyclodextrin with. Methods in Molecular Biology, 2021, 2207, 1-11.	0.9	2
17	Silibinin-hydroxypropyl- β -cyclodextrin (SLB-HP- β -CD) complex prevents apoptosis in liver and kidney after hepatic ischemia-reperfusion injury. Food and Chemical Toxicology, 2020, 145, 111731.	3.6	15
18	Preparation and Biophysical Characterization of Quercetin Inclusion Complexes with β -Cyclodextrin Derivatives to be Formulated as Possible Nose-to-Brain Quercetin Delivery Systems. Molecular Pharmaceutics, 2020, 17, 4241-4255.	4.6	35

#	ARTICLE	IF	CITATIONS
19	Comparative pharmacokinetics of the three echinocandins in ICU patients. <i>Journal of Antimicrobial Chemotherapy</i> , 2020, 75, 2969-2976.	3.0	7
20	Antihypertensive activity and molecular interactions of irbesartan in complex with 2- α -hydroxypropyl- β -cyclodextrin. <i>Chemical Biology and Drug Design</i> , 2020, 96, 668-683.	3.2	6
21	Population pharmacokinetics of micafungin over repeated doses in critically ill patients: a need for a loading dose?. <i>Journal of Pharmacy and Pharmacology</i> , 2020, 72, 1750-1760.	2.4	4
22	Use of natural anti-oxidants in experimental animal models of hepatic ischemia-reperfusion injury. <i>Annals of Medicine and Surgery</i> , 2020, 60, 592-599.	1.1	4
23	Hyperhydration using different hydration agents does not affect the haematological markers of the athlete biological passport in euhydrated volunteers. <i>Journal of Sports Sciences</i> , 2020, 38, 1924-1932.	2.0	3
24	Glycoprotein non-metastatic melanoma B expression after hepatic ischemia reperfusion and the effect of silibinin. <i>Translational Gastroenterology and Hepatology</i> , 2020, 5, 7-7.	3.0	5
25	Anti-inflammatory flurbiprofen nasal powders for nose-to-brain delivery in Alzheimer's disease. <i>Journal of Drug Targeting</i> , 2019, 27, 984-994.	4.4	21
26	Host-Guest Interactions between Candesartan and Its Prodrug Candesartan Cilexetil in Complex with 2-Hydroxypropyl- β -cyclodextrin: On the Biological Potency for Angiotensin II Antagonism. <i>Molecular Pharmaceutics</i> , 2019, 16, 1255-1271.	4.6	17
27	Effect of hyperhydration on the pharmacokinetics and detection of orally administered budesonide in doping control analysis. <i>Scandinavian Journal of Medicine and Science in Sports</i> , 2019, 29, 1489-1500.	2.9	6
28	Statins Withdrawal Induces Atherosclerotic Plaque Destabilization in Animal Model of Atherosclerosis: Rebound Stimulation of Inflammation. <i>Journal of Cardiovascular Pharmacology and Therapeutics</i> , 2019, 24, 377-386.	2.0	11
29	Hyperhydration Effect on Pharmacokinetic Parameters and Detection Sensitivity of Recombinant Human Erythropoietin in Urine and Serum Doping Control Analysis of Males. <i>Journal of Pharmaceutical Sciences</i> , 2019, 108, 2162-2172.	3.3	7
30	Preparation, chemical characterization and determination of crocetin's pharmacokinetics after oral and intravenous administration of saffron (<i>Crocus sativus</i> L.) aqueous extract to C57/BL6J mice. <i>Journal of Pharmacy and Pharmacology</i> , 2019, 71, 753-764.	2.4	19
31	Hyperhydration-Induced Decrease in Urinary Luteinizing Hormone Concentrations of Male Athletes in Doping Control Analysis. <i>International Journal of Sport Nutrition and Exercise Metabolism</i> , 2019, 29, 388-396.	2.1	4
32	Silibinin Improves TNF- α and M30 Expression and Histological Parameters in Rat Kidneys After Hepatic Ischemia/Reperfusion. <i>Journal of Investigative Surgery</i> , 2018, 31, 201-209.	1.3	15
33	<i>Crocus sativus</i> L. aqueous extract reduces atherogenesis, increases atherosclerotic plaque stability and improves glucose control in diabetic atherosclerotic animals. <i>Atherosclerosis</i> , 2018, 268, 207-214.	0.8	31
34	Silibinin Effect on Fas/FasL, HMGB1, and CD45 Expressions in a Rat Model Subjected to Liver Ischemia-Reperfusion Injury. <i>Journal of Investigative Surgery</i> , 2018, 31, 491-502.	1.3	24
35	The effect of athletes' hyperhydration on the urinary steroid profile markers in doping control analysis. <i>Drug Testing and Analysis</i> , 2018, 10, 1458-1468.	2.6	8
36	Exploring the oxidation and iron binding profile of a cyclodextrin encapsulated quercetin complex unveiled a controlled complex dissociation through a chemical stimulus. <i>Biochimica Et Biophysica Acta - General Subjects</i> , 2018, 1862, 1913-1924.	2.4	28

#	ARTICLE	IF	CITATIONS
37	Exploring the interactions of irbesartan and irbesartan-2-hydroxypropyl- β -cyclodextrin complex with model membranes. <i>Biochimica Et Biophysica Acta - Biomembranes</i> , 2017, 1859, 1089-1098.	2.6	26
38	Saffron (<i>Crocus sativus</i>) intake provides nutritional preconditioning against myocardial ischemia-reperfusion injury in Wild Type and ApoE (\sim/\sim) mice: Involvement of Nrf2 activation. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2017, 27, 919-929.	2.6	29
39	The impact of maternal- and neonatal-associated factors on human milk's macronutrients and energy. <i>Journal of Maternal-Fetal and Neonatal Medicine</i> , 2017, 30, 1302-1308.	1.5	62
40	Mapping the interactions and bioactivity of quercetin-2-hydroxypropyl- β -cyclodextrin complex. <i>International Journal of Pharmaceutics</i> , 2016, 511, 303-311.	5.2	48
41	Drug Utilization Patterns and Costs of Erythropoiesis-Stimulating Agents in an Outpatient Setting in Greece. <i>The Consultant Pharmacist</i> , 2016, 31, 271-281.	0.4	1
42	Mother's breast milk supplemented with donor milk reduces hospital and health service usage costs in low-birthweight infants. <i>Midwifery</i> , 2016, 40, 109-113.	2.3	17
43	Bioassay for Determining Voriconazole Serum Levels in Patients Receiving Combination Therapy with Echinocandins. <i>Antimicrobial Agents and Chemotherapy</i> , 2016, 60, 632-636.	3.2	13
44	Improved outcomes of feeding low birth weight infants with predominantly raw human milk versus donor banked milk and formula. <i>Journal of Maternal-Fetal and Neonatal Medicine</i> , 2016, 29, 1131-1138.	1.5	30
45	Saffron: a natural product with potential pharmaceutical applications. <i>Journal of Pharmacy and Pharmacology</i> , 2015, 67, 1634-1649.	2.4	154
46	Investigation of the Interactions of Silibinin with 2-Hydroxypropyl- β -cyclodextrin through Biophysical Techniques and Computational Methods. <i>Molecular Pharmaceutics</i> , 2015, 12, 954-965.	4.6	55
47	Serum and tissue pharmacokinetics of silibinin after per os and i.v. administration to mice as a HP- β -CD lyophilized product. <i>International Journal of Pharmaceutics</i> , 2015, 493, 366-373.	5.2	36
48	Gas chromatographic-mass spectrometric quantitation of busulfan in human plasma for therapeutic drug monitoring: A new on-line derivatization procedure for the conversion of busulfan to 1,4-diiodobutane. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2014, 90, 207-214.	2.8	14
49	Keeping a Critical Eye on the Science and the Regulation of Oral Drug Absorption: A Review. <i>Journal of Pharmaceutical Sciences</i> , 2013, 102, 3018-3036.	3.3	28
50	Pharmacokinetics of doripenem in CSF of patients with non-inflamed meninges. <i>Journal of Antimicrobial Chemotherapy</i> , 2012, 67, 1722-1729.	3.0	11
51	Elucidating the Role of Dose in the Biopharmaceutics Classification of Drugs: The Concepts of Critical Dose, Effective In Vivo Solubility, and Dose-Dependent BCS. <i>Pharmaceutical Research</i> , 2012, 29, 3188-3198.	3.5	22
52	Supersaturated dissolution data and their interpretation: the TPGS-carbamazepine model case. <i>Journal of Pharmacy and Pharmacology</i> , 2011, 63, 352-361.	2.4	18
53	Robust and Sensitive High-Performance Liquid Chromatographic-UV Detection Technique for the Determination of Tigecycline in Rabbit Plasma. <i>Journal of AOAC INTERNATIONAL</i> , 2011, 94, 847-856.	1.5	8
54	Use of 1-Anilino-8-naphthalenesulphonate as an Ion Probe for the Potentiometric Study of the Binding of Sulphonamides to Bovine Serum Albumin and Plasma. <i>Journal of Pharmacy and Pharmacology</i> , 2011, 45, 434-438.	2.4	7

#	ARTICLE	IF	CITATIONS
55	Computationalâ€Regulatory Developments in the Prediction of Oral Drug Absorption. Molecular Informatics, 2011, 30, 112-121.	2.5	1
56	Penetration of Intact Blood-Brain Barrier by Doripenem. Antimicrobial Agents and Chemotherapy, 2011, 55, 3637-3638.	3.2	5
57	In-vitro study on the competitive binding of diflunisal and uraemic toxins to serum albumin and human plasma using a potentiometric ion-probe technique. Journal of Pharmacy and Pharmacology, 2010, 58, 1467-1474.	2.4	13
58	Plasma profiles of lycopene after single oral and intravenous administrations in dogs. Journal of Pharmacy and Pharmacology, 2010, 58, 1211-1217.	2.4	10
59	Biopharmaceutical Classification Based on Solubility and Dissolution: A Reappraisal of Criteria for Hypothesis Models in the Light of the Experimental Observations. Basic and Clinical Pharmacology and Toxicology, 2010, 106, 168-172.	2.5	9
60	Effect of Cyclodextrin Complexation on the Aqueous Solubility and Solubility/Dose Ratio of Praziquantel. AAPS PharmSciTech, 2009, 10, 1444-51.	3.3	26
61	Development of a reaction-limited model of dissolution: Application to official dissolution tests experiments. International Journal of Pharmaceutics, 2008, 355, 114-125.	5.2	44
62	Biopharmaceutics classification systems for new molecular entities (BCS-NMEs) and marketed drugs (BCS-MD): Theoretical basis and practical examples. International Journal of Pharmaceutics, 2008, 361, 70-77.	5.2	22
63	Effect of pH and water-soluble polymers on the aqueous solubility of nimesulide in the absence and presence of β -cyclodextrin derivatives. Journal of Pharmacy and Pharmacology, 2008, 60, 1433-1439.	2.4	8
64	Modelling and simulation in drug absorption processes. Xenobiotica, 2007, 37, 1052-1065.	1.1	19
65	Solubilization and quantification of lycopene in aqueous media in the form of cyclodextrin binary systems. International Journal of Pharmaceutics, 2006, 309, 115-122.	5.2	40
66	Identification of Biowaivers Among Class II Drugs: Theoretical Justification and Practical Examples. Pharmaceutical Research, 2004, 21, 1567-1572.	3.5	68
67	Quantitative Biopharmaceutics Classification System: The Central Role of Dose/Solubility Ratio. Pharmaceutical Research, 2003, 20, 1917-1925.	3.5	143
68	The power law can describe the â€entireâ€™ drug release curve from HPMC-based matrix tablets: a hypothesis. International Journal of Pharmaceutics, 2003, 255, 199-207.	5.2	84
69	Non-linear regression analysis with errors in both variables: estimation of co-operative binding parameters. Biopharmaceutics and Drug Disposition, 2000, 21, 7-14.	1.9	8
70	Modeling of supersaturated dissolution data. International Journal of Pharmaceutics, 1999, 181, 153-157.	5.2	20
71	Studies on the interaction of diflunisal ion with cyclodextrins using ion-selective electrode potentiometry. European Journal of Pharmaceutical Sciences, 1999, 7, 271-278.	4.0	28
72	A displacement approach for competitive drugâ€protein binding studies using the potentiometric 1-anilino-8-naphthalene-sulfonate probe technique. European Journal of Pharmaceutical Sciences, 1999, 9, 123-130.	4.0	24

#	ARTICLE	IF	CITATIONS
73	Determination of fractal reaction dimension in dissolution studies. European Journal of Pharmaceutical Sciences, 1995, 3, 163-169.	4.0	28
74	General Treatment of Competitive Binding as Applied to the Potentiometric Ion Probe Technique: Application to the Interaction of Nonsteroidal Anti- Inflammatory Drugs with Bovine Serum Albumin. Journal of Pharmaceutical Sciences, 1994, 83, 1150-1154.	3.3	9
75	Automated flow-injection technique for use in dissolution studies of sustained-release formulations: Application to iron(II) formulations. Journal of Pharmaceutical and Biomedical Analysis, 1994, 12, 635-641.	2.8	15
76	Determination of association constants in cyclodextrin/drug complexation using the Scatchard plot: application to beta-cyclodextrin-anilinonaphthalenesulfonates. Pharmaceutical Research, 1992, 09, 1568-1574.	3.5	45
77	Complexation studies of cyclodextrins with tricyclic antidepressants using ion-selective electrodes. Pharmaceutical Research, 1992, 09, 94-100.	3.5	35
78	Binding study of the fluorescence probe 1-anilino-8-naphthalensulfonate to human plasma and human and bovine serum albumin using potentiometric titration. Pharmaceutical Research, 1991, 08, 888-892.	3.5	25
79	Binding Studies of Ions with Cyclodextrins Using Ion-Selective Electrodes. Journal of Pharmaceutical Sciences, 1990, 79, 1087-1094.	3.3	29
80	Construction of a naproxen ion-selective electrode and its application to pharmaceutical analysis. Analyst, The, 1989, 114, 387.	3.5	27